Lung SBRT: Margin, Algorithm, and Chest Wall Risk
A 68-year-old former smoker has a 2.0 cm peripheral NSCLC in the left lower lobe, 1 cm from the lateral chest wall. Staging is T1bN0M0. The tumor is invisible on fluoroscopy. A 4DCT shows 14 mm craniocaudal excursion; the ITV is generated from 10 phases. The prescribed dose is 54 Gy in 3 fractions to the PTV, defined as ITV plus 5 mm. Planning uses 6 MV FFF VMAT with AAA, heterogeneity correction on. The PTV D95 is 54.0 Gy by AAA, but an Acuros XB recalculation gives PTV D95 = 50.4 Gy. Total lung V20 is 12%, mean lung dose 6.5 Gy. The chest wall receives V30 = 45 cc, and the rib maximum dose is 61 Gy. The patient cannot tolerate abdominal compression or breath-hold.
1. The 5 mm PTV margin is added to an ITV. Is this adequate for a 14 mm moving tumor, and what would you verify before approving?
Read the worked answer
The ITV already covers the geometric excursion, so the 5 mm is not meant to cover the 14 mm of motion; it covers setup error, registration uncertainty, residual motion, and deformation. For a 14 mm excursion without compression or breath-hold, I would verify that the ITV truly encompasses all 10 phases, including any phase-dependent shape change near the chest wall, and that daily localization can reproduce the ITV position. If daily CBCT with soft-tissue or fiducial matching is used, a 5 mm margin can be reasonable, but I would review the residual error data rather than accept it by default. I would also check for interplay effects with FFF VMAT and confirm that the ITV is not clipped at the diaphragm. If reproducibility is poor, gating or a larger margin is safer than a tight margin.
2. Two algorithms differ by 3.6 Gy in PTV D95. Which calculation should drive the plan, and how would you resolve the discrepancy?
Read the worked answer
Acuros XB should drive the plan because it solves the linear Boltzmann transport equation and handles low-density lung and small fields more accurately than AAA, which can overestimate dose in heterogeneous lung. A 6.7% difference in PTV D95 is clinically meaningful for a 54 Gy SBRT course. I would not average the two results. I would reoptimize with Acuros, confirm that the dose grid and heterogeneity settings are correct, and independently verify with a Monte Carlo calculation or a measurement in a heterogeneous phantom. If Acuros shows undercoverage, the plan needs more monitor units or altered beam geometry, not acceptance of the higher AAA value.
3. The plan meets PTV coverage by AAA but the rib maximum is 61 Gy and chest wall V30 is 45 cc. How do you judge the risk and what planning changes are reasonable?
Read the worked answer
These values are near commonly used chest wall and rib tolerance thresholds for 3-fraction SBRT, so the risk of rib fracture and chest wall pain is not negligible. I would weigh the risk against tumor control and discuss it with the patient. Reasonable planning changes include avoiding lateral or posterior beams that graze the rib, using non-coplanar arcs or oblique beam angles, and accepting a small reduction in PTV hotspot if coverage can be maintained. I would not sacrifice gross tumor coverage for a modest chest wall dose reduction, but I would document the trade-off. If the rib dose cannot be reduced below a reasonable threshold, I would consider an alternative fractionation after multidisciplinary review.